# Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct03264352` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03264352](<https://clinicaltrials.gov/study/NCT03264352>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03264352

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11414 participants.

## Technical summary

Registry record NCT03264352. Randomized; single masking; primary purpose treatment. Start 2018-02-01 (actual); primary completion 2028-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 11414 participants (planned count; ClinicalTrials.gov record NCT03264352, source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)
- Started: 2018-02-01 (actual) (ClinicalTrials.gov record NCT03264352, source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2028-09-01 (anticipated) (ClinicalTrials.gov record NCT03264352, source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)
- Completion: 2029-09-01 (anticipated) (ClinicalTrials.gov record NCT03264352, source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03264352, source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03264352-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
- Acronym: IPAD
- Condition: Diabetes Mellitus, Type 2
- Condition: Adverse Event
- Condition: Blood Pressure
- Condition: Prehypertension
- Condition: Cardiovascular Risk Factor
- Intervention (Drug): Allisartan Isoproxil
- Intervention (Drug): Amlodipine 5mg
- Intervention (Other): Standard treatment by current guideline
- Lead sponsor: XueQing Yu
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 6802babdd445448fa287b41efdf37a4518704a2fb5d9346b62c0d6fed0248e70
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
